Drug Profile
CS 615
Alternative Names: CS-615Latest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; Ube Industries
- Class Antiasthmatics
- Mechanism of Action Leukotriene receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 31 Dec 1999 Phase-II clinical trials for Asthma in USA (PO)
- 16 Aug 1999 Phase-II clinical trials for Asthma in Europe (PO)